




# Embosphere<sup>®</sup>

Microspheres



**NEW SIZE**  
**50-100µm**

Ordering info  
on back

Predictable. Targeted. Established.<sup>™</sup>

**IOS**

# Embosphere®

## Microspheres

### PREDICTABLE

Embosphere Microspheres temporarily compress up to 33% for smooth microcatheter passage. Once through the microcatheter, they return to their original spherical shape and stated diameter for predictable, reliable delivery.<sup>1</sup>


### TARGETED

Embosphere Microspheres show a direct correlation between the level of arterial occlusion and the size of the particles used, allowing for consistent and reliable targeted occlusion.<sup>2,3</sup>

### ESTABLISHED

Embosphere Microspheres are the most clinically studied and clinically utilized spherical embolic, having been proven:

- In over 350,000 procedures<sup>4</sup>
- With +20 years' clinical experience<sup>4</sup>
- In more than 200 clinical articles<sup>4</sup>





### Non-Aggregating Properties

The hydrophilic surface and spherical shape of Embosphere Microspheres prevent aggregation in the catheter lumen and vasculature.

### Superior Rebound Capability

Embosphere Microspheres' elastic properties allow temporary compression of up to 33% to facilitate smooth microcatheter passage (A).<sup>1</sup> Once through the microcatheter, Embosphere Microspheres return to their original spherical shape and stated diameter (B) for predictable, targeted delivery.<sup>1</sup>






With Embosphere Microspheres,  
**92.3% of patients experienced 100% infarction** of their entire uterine fibroid tumor burden.

## Durable Occlusion


Embosphere Microspheres are biocompatible and nonresorbable with cell adhesion properties that enable complete and durable mechanical occlusion.



*Embosphere Microspheres at six months (A) and six years (B) after embolization of facial AVM.*

Images courtesy of Dr. Alex Laurent, Hôpital Lariboisière, Paris, France

## Percentage of Patients with Complete Infarction Rates of Overall Uterine Fibroid Tumor Burden



*Complete infarction of all fibroids leads to better long-term clinical outcomes, including a higher rate of symptom control and a lower rate of additional gynecologic intervention compared with incomplete infarction of fibroid tissue.<sup>8</sup>*

### REFERENCES








1. Laurent, et al. Trisacryl Gelatin Microspheres for Therapeutic Embolization, I: Development and In Vitro Evaluation. *Am J Neuroradiol*. 1996 Mar; 17:533-540
2. Pelage JP, et al. Uterine Artery Embolization in Sheep: Comparison of Acute Effects with Polyvinyl Alcohol Particles and Calibrated Microspheres. *Radiol*. 2002;224:436-45
3. Verret V, et al. The Arterial Distribution of Embozene and Embosphere Microspheres in Sheep Kidney and Uterus Embolization Models. *J Vasc Interv Radiol*. 2011 Feb;22(2):220-8
4. Data on file
5. Siskin G, et al. Leiomyoma Infarction after Uterine Artery Embolization: A Prospective Randomized Study Comparing Tris-acryl Gelatin Microspheres versus Polyvinyl Alcohol Microspheres. *J Vasc Interv Radiol*. 2008; 19:42-46
6. Smeets AJ, et al. Embolization of Uterine Leiomyomas with Polyzyne F-coated Hydrogel Microspheres: Initial Experience. *J Vasc Interv Radiol*. 2010 Dec;21(12):1830-4
7. Chrisman HB, et al., Prospective Evaluation of the Embolic Agent Bead Block in the Treatment of Uterine Leiomyomas with Uterine Artery Embolization. *J Vasc Interv Radiol*. 2010 Apr;21(4):484-9
8. Katsumori T, et al. Infarction of Uterine Fibroids After Embolization: Relationship Between Postprocedural Enhanced MRI Findings and Long-Term Clinical Outcomes. *Cardiovasc Intervent Radiol*. 2008;31:66

# Embosphere®

## Microspheres







### ORDERING INFORMATION

#### SYRINGES

Syringe Size Range (µm)	Color Code	1 mL Syringe Product Number	2 mL Syringe Product Number
50-100 	Gray	--	<b>S020GH NEW</b>
40-120 	Orange	--	<b>S120GH</b>
100-300 	Yellow	<b>S210GH</b>	<b>S220GH</b>
300-500 	Blue	<b>S410GH</b>	<b>S420GH</b>
500-700 	Red	<b>S610GH</b>	<b>S620GH</b>
700-900 	Green	<b>S810GH</b>	<b>S820GH</b>
900-1200 	Purple	<b>S1010GH</b>	<b>S1020GH</b>

Embosphere Microspheres supplied in sterile saline in 20 mL syringe. Sold 5 per box.

#### VIALS

Vial Size Range (µm)	Color Code	1 mL Vial Product Number	2 mL Vial Product Number
40-120 	Orange	<b>V110GH</b>	<b>V120GH</b>
100-300 	Yellow	<b>V210GH</b>	<b>V220GH</b>
300-500 	Blue	<b>V410GH</b>	<b>V420GH</b>
500-700 	Red	<b>V610GH</b>	<b>V620GH</b>
700-900 	Green	<b>V810GH</b>	<b>V820GH</b>
900-1200 	Purple	<b>V1010GH</b>	<b>V1020GH</b>

Embosphere Microspheres supplied in sterile saline in 8 mL vial. Sold 5 per box.



### SPECIFIC SIZE RANGES

Embosphere Microspheres are available in seven specific size ranges to achieve predictable and efficient vessel occlusion.



Understand. Innovate. Deliver.™

Merit Medical Systems, Inc.  
1600 West Merit Parkway  
South Jordan, Utah 84095  
1.801.208.4300  
1.800.35.MERIT

Merit Medical Europe, Middle East, & Africa (EMEA)  
Amerikalaan 42, 6199 AE Maastricht-Airport  
The Netherlands  
+31 43 358 82 22

Merit Medical Ireland Ltd.  
Parkmore Business Park West  
Galway, Ireland  
+353 (0) 91 703 733

Merit.com

Austria  
0800 295 374

Belgium  
0800 72 906 (Dutch)  
0800 73 172 (Français)

Denmark  
80 88 00 24

Finland  
0800 770 586

France  
0800 91 60 30

Germany  
0800 182 0871

Ireland (Republic)  
1800 553 163

Italy  
800 897 005

Luxembourg  
8002 25 22

Netherlands  
0800 022 81 84

Norway  
800 11629

Portugal  
308 801 034

Russia  
+7 495 221 89 02

Spain  
+34 911238406

Sweden  
020 792 445

Switzerland  
(Deutsch)  
+41 22 518 02 30  
(Français)  
+41 22 518 02 52  
(Italiano)  
+41 22 518 00 35  
UK  
0800 973 115